| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Eyelids | 20 | 2026 | 108 | 5.000 |
Why?
|
| Diabetes Mellitus, Type 2 | 46 | 2025 | 1459 | 4.730 |
Why?
|
| Orbit | 11 | 2024 | 75 | 3.640 |
Why?
|
| Hypoglycemic Agents | 23 | 2025 | 480 | 3.210 |
Why?
|
| Lacrimal Apparatus Diseases | 10 | 2026 | 41 | 2.850 |
Why?
|
| Orbital Diseases | 7 | 2024 | 64 | 2.630 |
Why?
|
| Eyelid Diseases | 6 | 2026 | 58 | 2.300 |
Why?
|
| Insulin Resistance | 19 | 2020 | 690 | 2.290 |
Why?
|
| Blepharoptosis | 7 | 2024 | 67 | 2.230 |
Why?
|
| Thiazolidinediones | 11 | 2015 | 81 | 2.180 |
Why?
|
| Blepharoplasty | 4 | 2026 | 27 | 2.180 |
Why?
|
| Conjunctival Neoplasms | 4 | 2022 | 13 | 2.140 |
Why?
|
| Eyelid Neoplasms | 11 | 2024 | 29 | 2.140 |
Why?
|
| Oculomotor Muscles | 7 | 2024 | 79 | 2.090 |
Why?
|
| Orbital Neoplasms | 9 | 2024 | 50 | 2.080 |
Why?
|
| Blood Glucose | 28 | 2021 | 1117 | 1.820 |
Why?
|
| Fatty Acids, Nonesterified | 19 | 2012 | 112 | 1.780 |
Why?
|
| Eye Foreign Bodies | 5 | 2020 | 9 | 1.650 |
Why?
|
| Sebaceous Gland Neoplasms | 8 | 2022 | 13 | 1.620 |
Why?
|
| Exophthalmos | 5 | 2019 | 28 | 1.430 |
Why?
|
| Fatty Liver | 4 | 2025 | 224 | 1.420 |
Why?
|
| Dermoid Cyst | 2 | 2023 | 33 | 1.340 |
Why?
|
| Retinoblastoma | 6 | 2023 | 87 | 1.300 |
Why?
|
| Lacrimal Apparatus | 6 | 2026 | 125 | 1.270 |
Why?
|
| Adiponectin | 12 | 2017 | 123 | 1.220 |
Why?
|
| Hemangioma, Capillary | 5 | 2021 | 19 | 1.220 |
Why?
|
| Humans | 150 | 2026 | 131163 | 1.200 |
Why?
|
| Adipose Tissue | 4 | 2023 | 502 | 1.200 |
Why?
|
| Dacryocystorhinostomy | 5 | 2023 | 22 | 1.200 |
Why?
|
| Retinal Neoplasms | 5 | 2023 | 71 | 1.200 |
Why?
|
| Eye Injuries | 3 | 2019 | 51 | 1.200 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2022 | 750 | 1.160 |
Why?
|
| Conjunctiva | 6 | 2025 | 196 | 1.150 |
Why?
|
| Insulin | 20 | 2014 | 1149 | 1.120 |
Why?
|
| Cysticercosis | 5 | 2021 | 21 | 1.120 |
Why?
|
| Liver | 9 | 2018 | 1796 | 1.100 |
Why?
|
| Venoms | 5 | 2012 | 17 | 1.090 |
Why?
|
| Male | 105 | 2026 | 64957 | 1.090 |
Why?
|
| Orbital Pseudotumor | 2 | 2019 | 8 | 1.070 |
Why?
|
| Conjunctival Diseases | 2 | 2026 | 31 | 1.060 |
Why?
|
| Suture Techniques | 3 | 2024 | 178 | 1.050 |
Why?
|
| Glucagon-Like Peptide 1 | 5 | 2025 | 77 | 1.050 |
Why?
|
| Orbit Evisceration | 4 | 2024 | 6 | 1.030 |
Why?
|
| Eye Neoplasms | 7 | 2026 | 37 | 1.020 |
Why?
|
| Hematoma | 2 | 2018 | 85 | 1.000 |
Why?
|
| Jaw Abnormalities | 2 | 2018 | 4 | 1.000 |
Why?
|
| Adult | 63 | 2026 | 31282 | 0.960 |
Why?
|
| Coloboma | 1 | 2026 | 41 | 0.960 |
Why?
|
| Peptides | 6 | 2016 | 708 | 0.950 |
Why?
|
| Muscle, Skeletal | 9 | 2014 | 981 | 0.950 |
Why?
|
| Surgical Flaps | 2 | 2026 | 183 | 0.940 |
Why?
|
| Prospective Studies | 21 | 2026 | 6459 | 0.940 |
Why?
|
| Eye Burns | 1 | 2026 | 16 | 0.940 |
Why?
|
| Lacrimal Duct Obstruction | 4 | 2023 | 20 | 0.930 |
Why?
|
| Burns, Chemical | 1 | 2026 | 31 | 0.930 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 6 | 2024 | 30 | 0.920 |
Why?
|
| Female | 87 | 2026 | 70963 | 0.910 |
Why?
|
| Collagen | 3 | 2026 | 273 | 0.900 |
Why?
|
| Autoimmune Diseases | 2 | 2019 | 262 | 0.880 |
Why?
|
| Young Adult | 29 | 2026 | 10103 | 0.860 |
Why?
|
| Middle Aged | 61 | 2026 | 28601 | 0.860 |
Why?
|
| Prostheses and Implants | 1 | 2026 | 146 | 0.840 |
Why?
|
| Eye Abnormalities | 2 | 2022 | 105 | 0.840 |
Why?
|
| Diabetic Angiopathies | 3 | 2016 | 66 | 0.800 |
Why?
|
| Biomarkers, Tumor | 10 | 2026 | 1586 | 0.800 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2023 | 15 | 0.790 |
Why?
|
| Facial Neoplasms | 1 | 2023 | 23 | 0.770 |
Why?
|
| Ectropion | 1 | 2022 | 4 | 0.760 |
Why?
|
| Microscopy, Acoustic | 3 | 2022 | 15 | 0.750 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 3 | 2025 | 402 | 0.750 |
Why?
|
| Fraser Syndrome | 1 | 2022 | 1 | 0.740 |
Why?
|
| Follow-Up Studies | 16 | 2026 | 5196 | 0.740 |
Why?
|
| Nervous System Diseases | 2 | 2018 | 395 | 0.730 |
Why?
|
| Fistula | 1 | 2023 | 50 | 0.730 |
Why?
|
| Pyrazines | 4 | 2007 | 81 | 0.730 |
Why?
|
| Syndactyly | 1 | 2022 | 24 | 0.730 |
Why?
|
| PPAR gamma | 6 | 2020 | 88 | 0.720 |
Why?
|
| Microphthalmos | 1 | 2022 | 54 | 0.720 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 6 | 2013 | 288 | 0.700 |
Why?
|
| Tomography, X-Ray Computed | 16 | 2022 | 2065 | 0.700 |
Why?
|
| Timolol | 2 | 2021 | 5 | 0.700 |
Why?
|
| Treatment Outcome | 22 | 2026 | 12936 | 0.690 |
Why?
|
| Tertiary Care Centers | 4 | 2025 | 263 | 0.680 |
Why?
|
| Eye Hemorrhage | 2 | 2020 | 4 | 0.670 |
Why?
|
| Exoribonucleases | 1 | 2021 | 21 | 0.670 |
Why?
|
| Lipid Metabolism | 5 | 2010 | 387 | 0.670 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2020 | 9 | 0.660 |
Why?
|
| Adolescent | 29 | 2026 | 20987 | 0.660 |
Why?
|
| 14-3-3 Proteins | 1 | 2021 | 56 | 0.660 |
Why?
|
| Face | 1 | 2022 | 192 | 0.660 |
Why?
|
| Wood | 1 | 2020 | 8 | 0.650 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2020 | 18 | 0.650 |
Why?
|
| Optic Nerve Injuries | 1 | 2020 | 12 | 0.640 |
Why?
|
| Blepharophimosis | 2 | 2018 | 25 | 0.640 |
Why?
|
| Betacoronavirus | 2 | 2020 | 275 | 0.620 |
Why?
|
| MicroRNAs | 5 | 2020 | 889 | 0.620 |
Why?
|
| Epidermal Cyst | 1 | 2019 | 16 | 0.610 |
Why?
|
| Child | 29 | 2026 | 26341 | 0.600 |
Why?
|
| Carcinoma, Adenoid Cystic | 4 | 2026 | 33 | 0.600 |
Why?
|
| AMP-Activated Protein Kinases | 5 | 2020 | 170 | 0.590 |
Why?
|
| Retrospective Studies | 22 | 2026 | 17753 | 0.590 |
Why?
|
| Glucose Clamp Technique | 9 | 2010 | 77 | 0.590 |
Why?
|
| Tears | 2 | 2020 | 185 | 0.590 |
Why?
|
| Gene Expression Regulation | 6 | 2021 | 2323 | 0.580 |
Why?
|
| Lighting | 1 | 2019 | 19 | 0.580 |
Why?
|
| Mouth Mucosa | 1 | 2019 | 46 | 0.580 |
Why?
|
| Lacerations | 1 | 2019 | 30 | 0.570 |
Why?
|
| Diabetes Mellitus | 3 | 2025 | 889 | 0.570 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 1287 | 0.570 |
Why?
|
| Adhesives | 1 | 2018 | 9 | 0.570 |
Why?
|
| Histiocytosis, Sinus | 1 | 2018 | 34 | 0.550 |
Why?
|
| Neurilemmoma | 2 | 2018 | 39 | 0.540 |
Why?
|
| Skin Abnormalities | 1 | 2018 | 34 | 0.540 |
Why?
|
| Ocular Motility Disorders | 1 | 2018 | 38 | 0.530 |
Why?
|
| Inflammasomes | 5 | 2021 | 154 | 0.530 |
Why?
|
| Paracentesis | 2 | 2019 | 20 | 0.530 |
Why?
|
| Thinness | 2 | 2025 | 71 | 0.520 |
Why?
|
| Ocular Hypertension | 1 | 2017 | 17 | 0.520 |
Why?
|
| Muscle Proteins | 2 | 2013 | 401 | 0.520 |
Why?
|
| Cataract Extraction | 1 | 2018 | 127 | 0.520 |
Why?
|
| Glucose | 8 | 2011 | 853 | 0.510 |
Why?
|
| Metformin | 3 | 2014 | 174 | 0.510 |
Why?
|
| Incretins | 2 | 2018 | 26 | 0.510 |
Why?
|
| Cardiovascular System | 1 | 2018 | 97 | 0.510 |
Why?
|
| PTEN Phosphohydrolase | 4 | 2014 | 252 | 0.510 |
Why?
|
| Decompression, Surgical | 1 | 2017 | 83 | 0.500 |
Why?
|
| India | 11 | 2025 | 234 | 0.500 |
Why?
|
| PPAR alpha | 3 | 2017 | 54 | 0.490 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 722 | 0.490 |
Why?
|
| Emphysema | 1 | 2017 | 67 | 0.490 |
Why?
|
| Immunoglobulin G | 2 | 2019 | 786 | 0.490 |
Why?
|
| Needles | 1 | 2016 | 48 | 0.490 |
Why?
|
| Abnormalities, Multiple | 1 | 2022 | 963 | 0.480 |
Why?
|
| Mutation | 4 | 2021 | 6099 | 0.470 |
Why?
|
| Adenocarcinoma, Sebaceous | 4 | 2022 | 8 | 0.470 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2017 | 254 | 0.470 |
Why?
|
| Urogenital Abnormalities | 1 | 2018 | 155 | 0.470 |
Why?
|
| Hypergammaglobulinemia | 1 | 2015 | 11 | 0.460 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2015 | 14 | 0.460 |
Why?
|
| Aged | 30 | 2026 | 21025 | 0.450 |
Why?
|
| Uveal Neoplasms | 3 | 2020 | 32 | 0.450 |
Why?
|
| Up-Regulation | 3 | 2014 | 825 | 0.450 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 1129 | 0.450 |
Why?
|
| Dry Eye Syndromes | 1 | 2019 | 296 | 0.440 |
Why?
|
| Prefrontal Cortex | 2 | 2017 | 215 | 0.440 |
Why?
|
| Myocardial Reperfusion Injury | 2 | 2016 | 130 | 0.440 |
Why?
|
| Drug Therapy, Combination | 10 | 2018 | 1173 | 0.440 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2015 | 30 | 0.430 |
Why?
|
| Glucosides | 4 | 2021 | 55 | 0.430 |
Why?
|
| Heart Defects, Congenital | 2 | 2018 | 1889 | 0.430 |
Why?
|
| Benzhydryl Compounds | 4 | 2021 | 79 | 0.420 |
Why?
|
| Fluorobenzenes | 1 | 2014 | 39 | 0.420 |
Why?
|
| Tuberculosis, Ocular | 1 | 2014 | 3 | 0.420 |
Why?
|
| Lipoxins | 3 | 2012 | 11 | 0.410 |
Why?
|
| Hypolipidemic Agents | 4 | 2009 | 202 | 0.410 |
Why?
|
| Eye Infections, Parasitic | 3 | 2018 | 8 | 0.410 |
Why?
|
| Purines | 1 | 2014 | 118 | 0.400 |
Why?
|
| Lipids | 3 | 2012 | 569 | 0.400 |
Why?
|
| Diagnosis, Differential | 12 | 2018 | 1882 | 0.390 |
Why?
|
| Quinazolines | 1 | 2014 | 176 | 0.390 |
Why?
|
| Ophthalmologic Surgical Procedures | 6 | 2025 | 91 | 0.390 |
Why?
|
| Obesity | 7 | 2025 | 2426 | 0.380 |
Why?
|
| Sulfonamides | 2 | 2014 | 296 | 0.380 |
Why?
|
| Splanchnic Circulation | 2 | 2003 | 49 | 0.380 |
Why?
|
| Cardiovascular Diseases | 3 | 2018 | 2121 | 0.370 |
Why?
|
| Nitric Oxide Synthase | 2 | 2010 | 170 | 0.370 |
Why?
|
| Lipogenesis | 1 | 2012 | 61 | 0.360 |
Why?
|
| Cardiotonic Agents | 2 | 2016 | 138 | 0.360 |
Why?
|
| Quality of Life | 1 | 2022 | 2082 | 0.360 |
Why?
|
| Carotid Arteries | 1 | 2013 | 124 | 0.360 |
Why?
|
| Proteins | 4 | 2004 | 1006 | 0.360 |
Why?
|
| Eye Injuries, Penetrating | 3 | 2017 | 16 | 0.350 |
Why?
|
| Nasolacrimal Duct | 3 | 2018 | 24 | 0.350 |
Why?
|
| Melanoma | 5 | 2020 | 931 | 0.350 |
Why?
|
| Carotid Artery Diseases | 1 | 2013 | 130 | 0.350 |
Why?
|
| Cicatrix | 2 | 2023 | 123 | 0.350 |
Why?
|
| Aspergillosis | 2 | 2022 | 43 | 0.350 |
Why?
|
| Pilot Projects | 3 | 2026 | 1445 | 0.340 |
Why?
|
| Pyrimidines | 1 | 2014 | 446 | 0.330 |
Why?
|
| Eye Infections, Fungal | 2 | 2024 | 68 | 0.330 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 3 | 2020 | 94 | 0.330 |
Why?
|
| Diabetic Cardiomyopathies | 3 | 2020 | 19 | 0.330 |
Why?
|
| Eye Infections, Bacterial | 2 | 2025 | 81 | 0.310 |
Why?
|
| Fibroblast Growth Factors | 1 | 2011 | 172 | 0.310 |
Why?
|
| Muscle Cells | 1 | 2010 | 24 | 0.310 |
Why?
|
| Acyl Coenzyme A | 2 | 2010 | 23 | 0.310 |
Why?
|
| Prognosis | 9 | 2026 | 4886 | 0.310 |
Why?
|
| Myocardium | 6 | 2020 | 852 | 0.310 |
Why?
|
| Dipeptidyl Peptidase 4 | 3 | 2019 | 22 | 0.300 |
Why?
|
| Phosphodiesterase 3 Inhibitors | 3 | 2014 | 8 | 0.300 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 3436 | 0.300 |
Why?
|
| Prednisolone | 4 | 2018 | 74 | 0.300 |
Why?
|
| Glucocorticoids | 3 | 2018 | 348 | 0.290 |
Why?
|
| Tetrazoles | 3 | 2014 | 70 | 0.280 |
Why?
|
| Animals | 27 | 2026 | 33912 | 0.280 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 3 | 2019 | 127 | 0.280 |
Why?
|
| Ophthalmology | 2 | 2021 | 175 | 0.270 |
Why?
|
| Immunohistochemistry | 10 | 2026 | 1591 | 0.270 |
Why?
|
| Adamantane | 2 | 2018 | 9 | 0.270 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 744 | 0.260 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2021 | 90 | 0.260 |
Why?
|
| Ultrasonography | 5 | 2018 | 943 | 0.260 |
Why?
|
| Smoking | 1 | 2012 | 932 | 0.260 |
Why?
|
| Linagliptin | 2 | 2019 | 5 | 0.260 |
Why?
|
| Myocytes, Cardiac | 4 | 2017 | 668 | 0.260 |
Why?
|
| Dipeptides | 2 | 2018 | 60 | 0.260 |
Why?
|
| Glucose Tolerance Test | 6 | 2010 | 198 | 0.250 |
Why?
|
| Antifungal Agents | 3 | 2024 | 292 | 0.250 |
Why?
|
| Reflex, Abnormal | 2 | 2018 | 13 | 0.250 |
Why?
|
| Oxazoles | 2 | 2017 | 21 | 0.250 |
Why?
|
| Magnetic Resonance Spectroscopy | 4 | 2011 | 260 | 0.250 |
Why?
|
| Proto-Oncogene Proteins c-myb | 1 | 2026 | 9 | 0.240 |
Why?
|
| Visual Acuity | 5 | 2024 | 523 | 0.240 |
Why?
|
| Eye | 2 | 2022 | 215 | 0.240 |
Why?
|
| Signal Transduction | 13 | 2020 | 4686 | 0.240 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2021 | 325 | 0.240 |
Why?
|
| Cardiovascular Agents | 2 | 2018 | 88 | 0.240 |
Why?
|
| Aged, 80 and over | 10 | 2026 | 6797 | 0.240 |
Why?
|
| Thiophenes | 2 | 2017 | 69 | 0.240 |
Why?
|
| Triglycerides | 5 | 2012 | 602 | 0.230 |
Why?
|
| Dyslipidemias | 1 | 2009 | 256 | 0.230 |
Why?
|
| Cadherins | 3 | 2017 | 182 | 0.220 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 339 | 0.220 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 351 | 0.220 |
Why?
|
| Pandemics | 3 | 2024 | 1118 | 0.220 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 5 | 2018 | 44 | 0.220 |
Why?
|
| Gastric Inhibitory Polypeptide | 1 | 2025 | 19 | 0.220 |
Why?
|
| Anti-Bacterial Agents | 4 | 2025 | 2596 | 0.220 |
Why?
|
| Silicone Elastomers | 1 | 2024 | 21 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2020 | 480 | 0.210 |
Why?
|
| Hormones, Ectopic | 1 | 2004 | 7 | 0.210 |
Why?
|
| Sodium-Glucose Transporter 2 | 3 | 2021 | 18 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 1272 | 0.210 |
Why?
|
| Phosphorylation | 6 | 2020 | 1571 | 0.210 |
Why?
|
| Rare Diseases | 3 | 2022 | 210 | 0.210 |
Why?
|
| Amphotericin B | 1 | 2024 | 89 | 0.210 |
Why?
|
| Mucormycosis | 1 | 2024 | 31 | 0.210 |
Why?
|
| Point-of-Care Systems | 1 | 2007 | 214 | 0.200 |
Why?
|
| Albendazole | 3 | 2018 | 26 | 0.200 |
Why?
|
| Time Factors | 12 | 2018 | 6196 | 0.200 |
Why?
|
| Muscles | 2 | 2004 | 197 | 0.200 |
Why?
|
| Optic Nerve | 2 | 2023 | 110 | 0.200 |
Why?
|
| DNA Mutational Analysis | 3 | 2021 | 775 | 0.200 |
Why?
|
| Cells, Cultured | 8 | 2020 | 2885 | 0.200 |
Why?
|
| Malnutrition | 1 | 2025 | 163 | 0.190 |
Why?
|
| Eye, Artificial | 1 | 2023 | 2 | 0.190 |
Why?
|
| Body Weight | 3 | 2012 | 987 | 0.190 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2003 | 43 | 0.190 |
Why?
|
| Sutures | 2 | 2020 | 63 | 0.190 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2020 | 65 | 0.190 |
Why?
|
| Infant | 10 | 2025 | 13352 | 0.190 |
Why?
|
| Diabetes Mellitus, Type 1 | 4 | 2021 | 895 | 0.190 |
Why?
|
| Homeodomain Proteins | 2 | 2017 | 555 | 0.190 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2025 | 401 | 0.190 |
Why?
|
| Thiazoles | 1 | 2003 | 113 | 0.190 |
Why?
|
| Receptors, Glucagon | 4 | 2012 | 33 | 0.190 |
Why?
|
| Angiolymphoid Hyperplasia with Eosinophilia | 1 | 2022 | 3 | 0.190 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2003 | 145 | 0.180 |
Why?
|
| Skin Neoplasms | 2 | 2022 | 909 | 0.180 |
Why?
|
| Viscera | 1 | 2002 | 56 | 0.180 |
Why?
|
| Dermatofibrosarcoma | 1 | 2022 | 17 | 0.180 |
Why?
|
| Cyclin B1 | 1 | 2022 | 7 | 0.180 |
Why?
|
| Mitochondria | 2 | 2004 | 785 | 0.180 |
Why?
|
| Body Mass Index | 5 | 2011 | 1717 | 0.180 |
Why?
|
| Robotic Surgical Procedures | 1 | 2026 | 226 | 0.180 |
Why?
|
| Child, Preschool | 10 | 2025 | 15110 | 0.180 |
Why?
|
| Cyclin D1 | 1 | 2022 | 106 | 0.180 |
Why?
|
| Bacteria | 1 | 2025 | 521 | 0.170 |
Why?
|
| Ketosis | 1 | 2021 | 15 | 0.170 |
Why?
|
| Diabetes Mellitus, Experimental | 4 | 2019 | 137 | 0.170 |
Why?
|
| Equipment Design | 2 | 2026 | 512 | 0.170 |
Why?
|
| Taenia solium | 1 | 2021 | 13 | 0.170 |
Why?
|
| Kidney | 2 | 2018 | 1282 | 0.170 |
Why?
|
| Neoplasm Invasiveness | 1 | 2023 | 631 | 0.170 |
Why?
|
| Liposarcoma | 1 | 2021 | 24 | 0.170 |
Why?
|
| Eye Diseases | 1 | 2023 | 107 | 0.170 |
Why?
|
| Mannans | 1 | 2021 | 15 | 0.170 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 400 | 0.170 |
Why?
|
| Fasting | 4 | 2017 | 303 | 0.160 |
Why?
|
| Ethmoid Sinus | 1 | 2020 | 9 | 0.160 |
Why?
|
| Saccharum | 1 | 2020 | 13 | 0.160 |
Why?
|
| Electroacupuncture | 1 | 2020 | 8 | 0.160 |
Why?
|
| Receptor, Notch1 | 1 | 2021 | 78 | 0.160 |
Why?
|
| Adipocytes, Brown | 1 | 2020 | 27 | 0.160 |
Why?
|
| Mice | 13 | 2021 | 18301 | 0.160 |
Why?
|
| Mucous Membrane | 1 | 2020 | 95 | 0.160 |
Why?
|
| Hemangioma | 1 | 2021 | 86 | 0.160 |
Why?
|
| Administration, Topical | 1 | 2020 | 130 | 0.160 |
Why?
|
| Debridement | 2 | 2024 | 95 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2019 | 2026 | 0.160 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2022 | 130 | 0.160 |
Why?
|
| DNA, Neoplasm | 1 | 2021 | 282 | 0.160 |
Why?
|
| Apoptosis | 5 | 2020 | 1827 | 0.160 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2020 | 484 | 0.160 |
Why?
|
| Hypoglycemia | 3 | 2014 | 190 | 0.160 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2018 | 63 | 0.160 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2020 | 108 | 0.150 |
Why?
|
| Accidents, Traffic | 1 | 2020 | 102 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 9 | 2021 | 4738 | 0.150 |
Why?
|
| Adipocytes, White | 2 | 2020 | 27 | 0.150 |
Why?
|
| Heart | 2 | 2016 | 650 | 0.150 |
Why?
|
| Wounds, Penetrating | 1 | 2020 | 140 | 0.150 |
Why?
|
| Myocardial Infarction | 4 | 2019 | 999 | 0.150 |
Why?
|
| Adenoma, Pleomorphic | 2 | 2016 | 9 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2018 | 1267 | 0.150 |
Why?
|
| Ventricular Remodeling | 1 | 2020 | 155 | 0.150 |
Why?
|
| Pain | 1 | 2022 | 450 | 0.150 |
Why?
|
| RNA, Messenger | 5 | 2015 | 2550 | 0.150 |
Why?
|
| Propranolol | 1 | 2019 | 110 | 0.150 |
Why?
|
| Lymphangioma | 1 | 2019 | 21 | 0.150 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2021 | 170 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2023 | 3763 | 0.150 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2019 | 38 | 0.150 |
Why?
|
| Ventricular Function, Left | 2 | 2020 | 549 | 0.140 |
Why?
|
| Sodium-Hydrogen Exchanger 1 | 1 | 2018 | 3 | 0.140 |
Why?
|
| Bleomycin | 1 | 2019 | 116 | 0.140 |
Why?
|
| Vimentin | 1 | 2019 | 59 | 0.140 |
Why?
|
| RNA, Neoplasm | 1 | 2019 | 125 | 0.140 |
Why?
|
| Administration, Ophthalmic | 1 | 2018 | 7 | 0.140 |
Why?
|
| Eyelashes | 1 | 2018 | 3 | 0.140 |
Why?
|
| Biomarkers | 4 | 2020 | 3385 | 0.140 |
Why?
|
| Salivary Ducts | 1 | 2018 | 4 | 0.140 |
Why?
|
| Adipose Tissue, Brown | 2 | 2017 | 89 | 0.140 |
Why?
|
| Conjunctivitis | 1 | 2018 | 20 | 0.140 |
Why?
|
| Echinococcosis | 1 | 2018 | 6 | 0.140 |
Why?
|
| Histoplasma | 1 | 2018 | 37 | 0.140 |
Why?
|
| RNA Interference | 3 | 2017 | 491 | 0.140 |
Why?
|
| Subcutaneous Fat | 1 | 2018 | 33 | 0.140 |
Why?
|
| Cysts | 2 | 2019 | 80 | 0.140 |
Why?
|
| Diplopia | 1 | 2018 | 46 | 0.140 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2019 | 216 | 0.140 |
Why?
|
| Antiprotozoal Agents | 1 | 2018 | 41 | 0.140 |
Why?
|
| Endemic Diseases | 1 | 2018 | 60 | 0.140 |
Why?
|
| Immunologic Factors | 1 | 2019 | 190 | 0.140 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 373 | 0.130 |
Why?
|
| Histoplasmosis | 1 | 2018 | 55 | 0.130 |
Why?
|
| Aspartate Aminotransferases | 2 | 2011 | 80 | 0.130 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 129 | 0.130 |
Why?
|
| Pancreatitis, Chronic | 1 | 2018 | 88 | 0.130 |
Why?
|
| Hyperglycemia | 3 | 2017 | 234 | 0.130 |
Why?
|
| Healthy Volunteers | 1 | 2018 | 154 | 0.130 |
Why?
|
| Myxoma | 1 | 2017 | 29 | 0.130 |
Why?
|
| Cold Temperature | 1 | 2017 | 80 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2018 | 116 | 0.130 |
Why?
|
| Biopsy | 6 | 2021 | 1239 | 0.130 |
Why?
|
| Fibroblasts | 2 | 2018 | 849 | 0.130 |
Why?
|
| Thermogenesis | 1 | 2017 | 57 | 0.130 |
Why?
|
| Liver Cirrhosis | 1 | 2024 | 903 | 0.130 |
Why?
|
| Alanine Transaminase | 2 | 2011 | 153 | 0.130 |
Why?
|
| Pancreatitis | 1 | 2018 | 139 | 0.130 |
Why?
|
| Weight Gain | 2 | 2014 | 393 | 0.130 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 333 | 0.130 |
Why?
|
| Cleft Lip | 1 | 2020 | 195 | 0.130 |
Why?
|
| Cleft Palate | 1 | 2020 | 221 | 0.130 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2017 | 42 | 0.130 |
Why?
|
| Disease Models, Animal | 7 | 2020 | 4697 | 0.130 |
Why?
|
| Emergency Treatment | 1 | 2017 | 78 | 0.130 |
Why?
|
| Remission, Spontaneous | 1 | 2016 | 62 | 0.130 |
Why?
|
| Orbital Fractures | 1 | 2017 | 40 | 0.120 |
Why?
|
| Glucagon-Like Peptide-2 Receptor | 1 | 2016 | 13 | 0.120 |
Why?
|
| Vitreous Body | 1 | 2016 | 54 | 0.120 |
Why?
|
| Diabetic Nephropathies | 1 | 2018 | 115 | 0.120 |
Why?
|
| Liraglutide | 1 | 2016 | 15 | 0.120 |
Why?
|
| Nose | 1 | 2017 | 115 | 0.120 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2017 | 74 | 0.120 |
Why?
|
| DNA Damage | 1 | 2020 | 511 | 0.120 |
Why?
|
| Tumor Burden | 1 | 2017 | 240 | 0.120 |
Why?
|
| Disease Progression | 3 | 2019 | 2200 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 3 | 2014 | 1447 | 0.120 |
Why?
|
| Protective Agents | 1 | 2016 | 33 | 0.120 |
Why?
|
| C-Peptide | 4 | 2007 | 107 | 0.120 |
Why?
|
| Muscle Fibers, Skeletal | 2 | 2018 | 99 | 0.120 |
Why?
|
| Carcinoma | 1 | 2018 | 291 | 0.120 |
Why?
|
| Sclerosis | 1 | 2015 | 31 | 0.120 |
Why?
|
| Craniofacial Abnormalities | 1 | 2017 | 251 | 0.110 |
Why?
|
| Delayed Diagnosis | 1 | 2017 | 131 | 0.110 |
Why?
|
| Drainage | 2 | 2014 | 250 | 0.110 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2017 | 218 | 0.110 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2015 | 37 | 0.110 |
Why?
|
| Cyclic AMP | 2 | 2012 | 220 | 0.110 |
Why?
|
| Global Health | 1 | 2020 | 626 | 0.110 |
Why?
|
| Tomography, Optical Coherence | 1 | 2019 | 441 | 0.110 |
Why?
|
| Models, Genetic | 1 | 2018 | 749 | 0.110 |
Why?
|
| Dietary Fats | 2 | 2008 | 278 | 0.110 |
Why?
|
| Craniocerebral Trauma | 1 | 2016 | 144 | 0.110 |
Why?
|
| Skin Transplantation | 1 | 2015 | 57 | 0.110 |
Why?
|
| Diet, Western | 1 | 2014 | 20 | 0.110 |
Why?
|
| Rosuvastatin Calcium | 1 | 2014 | 42 | 0.110 |
Why?
|
| Postoperative Complications | 3 | 2023 | 3147 | 0.110 |
Why?
|
| Research Design | 1 | 2018 | 716 | 0.100 |
Why?
|
| Genetic Association Studies | 1 | 2018 | 819 | 0.100 |
Why?
|
| Curettage | 1 | 2014 | 8 | 0.100 |
Why?
|
| Energy Metabolism | 2 | 2018 | 804 | 0.100 |
Why?
|
| Cytodiagnosis | 1 | 2014 | 18 | 0.100 |
Why?
|
| Wnt Signaling Pathway | 1 | 2015 | 223 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 789 | 0.100 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 2013 | 4 | 0.100 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2013 | 41 | 0.100 |
Why?
|
| Intubation | 1 | 2013 | 16 | 0.100 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 378 | 0.100 |
Why?
|
| Polyethylene | 1 | 2013 | 15 | 0.100 |
Why?
|
| Treatment Failure | 1 | 2014 | 351 | 0.100 |
Why?
|
| Logistic Models | 1 | 2018 | 1797 | 0.100 |
Why?
|
| Retina | 2 | 2013 | 425 | 0.100 |
Why?
|
| Orbital Cellulitis | 1 | 2013 | 15 | 0.100 |
Why?
|
| Inflammation Mediators | 3 | 2020 | 226 | 0.100 |
Why?
|
| Alkylating Agents | 1 | 2012 | 6 | 0.100 |
Why?
|
| Coloring Agents | 1 | 2013 | 71 | 0.100 |
Why?
|
| Ubiquitin | 1 | 2013 | 128 | 0.090 |
Why?
|
| Metabolic Syndrome | 1 | 2016 | 369 | 0.090 |
Why?
|
| Mitomycin | 1 | 2012 | 36 | 0.090 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 152 | 0.090 |
Why?
|
| Drug Administration Schedule | 2 | 2012 | 732 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 740 | 0.090 |
Why?
|
| Diabetic Retinopathy | 1 | 2013 | 75 | 0.090 |
Why?
|
| Papillomavirus Infections | 2 | 2018 | 394 | 0.090 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2013 | 241 | 0.090 |
Why?
|
| Double-Blind Method | 2 | 2014 | 1626 | 0.090 |
Why?
|
| Multimodal Imaging | 1 | 2013 | 109 | 0.090 |
Why?
|
| Receptors, Cell Surface | 2 | 2004 | 420 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2004 | 639 | 0.090 |
Why?
|
| Human papillomavirus 16 | 1 | 2012 | 97 | 0.090 |
Why?
|
| Triazoles | 1 | 2012 | 141 | 0.090 |
Why?
|
| Gene Silencing | 1 | 2012 | 229 | 0.090 |
Why?
|
| Antitubercular Agents | 1 | 2014 | 275 | 0.090 |
Why?
|
| Nausea | 1 | 2011 | 83 | 0.090 |
Why?
|
| Hepatocytes | 1 | 2013 | 232 | 0.080 |
Why?
|
| Reference Values | 5 | 2004 | 676 | 0.080 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 279 | 0.080 |
Why?
|
| beta Catenin | 1 | 2012 | 197 | 0.080 |
Why?
|
| DNA, Viral | 1 | 2012 | 448 | 0.080 |
Why?
|
| Epinephrine | 3 | 2021 | 150 | 0.080 |
Why?
|
| Texas | 3 | 2012 | 3686 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2015 | 760 | 0.080 |
Why?
|
| Edema | 1 | 2011 | 130 | 0.080 |
Why?
|
| Forkhead Transcription Factors | 1 | 2013 | 371 | 0.080 |
Why?
|
| Diglycerides | 1 | 2010 | 18 | 0.080 |
Why?
|
| Disease Management | 1 | 2014 | 558 | 0.080 |
Why?
|
| Survival Rate | 3 | 2022 | 2114 | 0.080 |
Why?
|
| Lower Extremity | 1 | 2011 | 185 | 0.080 |
Why?
|
| Injections, Intralesional | 2 | 2019 | 46 | 0.080 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2014 | 430 | 0.080 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 887 | 0.070 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 318 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 1071 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 2833 | 0.070 |
Why?
|
| Hormones | 4 | 2007 | 162 | 0.070 |
Why?
|
| Leptin | 2 | 2013 | 218 | 0.070 |
Why?
|
| Helper Viruses | 1 | 2008 | 45 | 0.070 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 1224 | 0.070 |
Why?
|
| Heart Diseases | 1 | 2013 | 499 | 0.070 |
Why?
|
| Glucagon | 2 | 2006 | 146 | 0.070 |
Why?
|
| Cholesterol | 3 | 2012 | 539 | 0.070 |
Why?
|
| Receptors, Adiponectin | 2 | 2004 | 3 | 0.070 |
Why?
|
| Models, Biological | 1 | 2012 | 1371 | 0.070 |
Why?
|
| Eating | 2 | 2008 | 377 | 0.070 |
Why?
|
| Nitric Oxide | 1 | 2010 | 471 | 0.060 |
Why?
|
| Anthelmintics | 2 | 2018 | 56 | 0.060 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 289 | 0.060 |
Why?
|
| Adipose Tissue, White | 2 | 2018 | 97 | 0.060 |
Why?
|
| Lymphatic Metastasis | 2 | 2022 | 426 | 0.060 |
Why?
|
| Multienzyme Complexes | 1 | 2007 | 76 | 0.060 |
Why?
|
| Fenofibrate | 1 | 2007 | 59 | 0.060 |
Why?
|
| Fibrosis | 2 | 2020 | 429 | 0.060 |
Why?
|
| Free Radical Scavengers | 1 | 2007 | 54 | 0.060 |
Why?
|
| Goats | 1 | 2026 | 31 | 0.060 |
Why?
|
| Neoplasm Grading | 2 | 2020 | 274 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 905 | 0.060 |
Why?
|
| SOXC Transcription Factors | 1 | 2026 | 13 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2026 | 61 | 0.060 |
Why?
|
| Gastric Emptying | 1 | 2006 | 79 | 0.060 |
Why?
|
| Antihypertensive Agents | 1 | 2009 | 414 | 0.060 |
Why?
|
| Adenoviridae | 1 | 2008 | 579 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2018 | 301 | 0.060 |
Why?
|
| Fat Emulsions, Intravenous | 2 | 2003 | 81 | 0.060 |
Why?
|
| Insulin-Secreting Cells | 1 | 2006 | 133 | 0.050 |
Why?
|
| Enzyme Activation | 2 | 2018 | 576 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2019 | 711 | 0.050 |
Why?
|
| Adenylate Kinase | 1 | 2004 | 12 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2026 | 743 | 0.050 |
Why?
|
| Resistin | 1 | 2004 | 30 | 0.050 |
Why?
|
| Circadian Rhythm | 1 | 2007 | 327 | 0.050 |
Why?
|
| Cell Survival | 2 | 2017 | 826 | 0.050 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2026 | 236 | 0.050 |
Why?
|
| Hyperlipidemias | 1 | 2005 | 185 | 0.050 |
Why?
|
| Mice, Knockout | 3 | 2017 | 3819 | 0.050 |
Why?
|
| Extracellular Matrix | 1 | 2004 | 232 | 0.050 |
Why?
|
| Genetic Therapy | 1 | 2008 | 713 | 0.050 |
Why?
|
| Infant, Low Birth Weight | 1 | 2004 | 172 | 0.050 |
Why?
|
| Transfection | 2 | 2017 | 962 | 0.050 |
Why?
|
| Consensus | 1 | 2025 | 512 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 1216 | 0.050 |
Why?
|
| Incidence | 2 | 2024 | 3360 | 0.050 |
Why?
|
| Mexican Americans | 1 | 2004 | 162 | 0.050 |
Why?
|
| 3' Untranslated Regions | 2 | 2013 | 154 | 0.050 |
Why?
|
| Sebaceous Glands | 1 | 2022 | 3 | 0.050 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2025 | 859 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2004 | 412 | 0.050 |
Why?
|
| Syndrome | 2 | 2017 | 1155 | 0.050 |
Why?
|
| Cell Nucleus | 1 | 2004 | 556 | 0.050 |
Why?
|
| Injections, Intravenous | 1 | 2002 | 239 | 0.050 |
Why?
|
| Cholesterol, HDL | 1 | 2004 | 383 | 0.050 |
Why?
|
| Fatty Acids | 1 | 2004 | 377 | 0.040 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 2 | 2012 | 157 | 0.040 |
Why?
|
| Thyroid Gland | 1 | 2022 | 96 | 0.040 |
Why?
|
| Streptozocin | 1 | 2021 | 25 | 0.040 |
Why?
|
| Corticosterone | 1 | 2021 | 49 | 0.040 |
Why?
|
| Ketones | 1 | 2021 | 25 | 0.040 |
Why?
|
| Voriconazole | 1 | 2021 | 29 | 0.040 |
Why?
|
| Kinetics | 1 | 2003 | 1088 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 1618 | 0.040 |
Why?
|
| Galactose | 1 | 2021 | 53 | 0.040 |
Why?
|
| Osmolar Concentration | 3 | 2007 | 148 | 0.040 |
Why?
|
| Organelle Biogenesis | 1 | 2020 | 18 | 0.040 |
Why?
|
| Coronary Disease | 1 | 2004 | 624 | 0.040 |
Why?
|
| Water | 1 | 2021 | 186 | 0.040 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2020 | 38 | 0.040 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2002 | 324 | 0.040 |
Why?
|
| Vision Disorders | 1 | 2022 | 191 | 0.040 |
Why?
|
| Epithelioid Cells | 1 | 2020 | 12 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2007 | 1801 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2020 | 101 | 0.040 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2020 | 93 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2022 | 315 | 0.040 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2020 | 157 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2003 | 604 | 0.040 |
Why?
|
| Sclerosing Solutions | 1 | 2019 | 10 | 0.040 |
Why?
|
| Awareness | 1 | 1999 | 78 | 0.040 |
Why?
|
| Clinical Studies as Topic | 1 | 2018 | 11 | 0.040 |
Why?
|
| Immunoblotting | 2 | 2012 | 292 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2006 | 2465 | 0.040 |
Why?
|
| United States | 2 | 2025 | 12072 | 0.040 |
Why?
|
| DNA Methylation | 2 | 2018 | 1077 | 0.040 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2018 | 72 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2019 | 123 | 0.030 |
Why?
|
| Prolapse | 1 | 2018 | 10 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 155 | 0.030 |
Why?
|
| Taenia | 1 | 2018 | 4 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2021 | 1483 | 0.030 |
Why?
|
| Surgery, Plastic | 1 | 2020 | 109 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 1 | 2018 | 81 | 0.030 |
Why?
|
| Calibration | 1 | 2018 | 92 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2018 | 294 | 0.030 |
Why?
|
| Cysticercus | 1 | 2017 | 2 | 0.030 |
Why?
|
| Infusions, Intravenous | 2 | 2013 | 531 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2013 | 633 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 2018 | 305 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2017 | 8635 | 0.030 |
Why?
|
| Polysaccharides | 1 | 2018 | 143 | 0.030 |
Why?
|
| Metals | 1 | 2017 | 70 | 0.030 |
Why?
|
| Mice, Obese | 1 | 2017 | 74 | 0.030 |
Why?
|
| Cytoprotection | 1 | 2017 | 36 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2018 | 299 | 0.030 |
Why?
|
| Cytochromes c | 1 | 2017 | 51 | 0.030 |
Why?
|
| Diet | 1 | 2004 | 1121 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 2304 | 0.030 |
Why?
|
| Environment | 1 | 2017 | 149 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2017 | 121 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2018 | 645 | 0.030 |
Why?
|
| Diet, High-Fat | 1 | 2018 | 268 | 0.030 |
Why?
|
| Metabolomics | 1 | 2020 | 501 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2018 | 928 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2018 | 269 | 0.030 |
Why?
|
| DNA, Mitochondrial | 1 | 2017 | 233 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 1999 | 464 | 0.030 |
Why?
|
| Age Distribution | 1 | 2017 | 422 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2020 | 798 | 0.030 |
Why?
|
| Zinc Finger E-box Binding Homeobox 2 | 1 | 2015 | 6 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 2017 | 259 | 0.030 |
Why?
|
| Esthetics | 1 | 2015 | 40 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2018 | 463 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 2017 | 480 | 0.030 |
Why?
|
| Protein Binding | 1 | 2018 | 1652 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2015 | 119 | 0.030 |
Why?
|
| Cytokines | 1 | 2020 | 1339 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2017 | 541 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 371 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2024 | 1373 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 2085 | 0.020 |
Why?
|
| Lymphoscintigraphy | 1 | 2013 | 2 | 0.020 |
Why?
|
| Forkhead Box Protein L2 | 1 | 2013 | 10 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2013 | 25 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2013 | 140 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 664 | 0.020 |
Why?
|
| Amblyopia | 1 | 2013 | 33 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2013 | 89 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2013 | 143 | 0.020 |
Why?
|
| Ceftriaxone | 1 | 2013 | 69 | 0.020 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2013 | 71 | 0.020 |
Why?
|
| Eye Movements | 1 | 2013 | 69 | 0.020 |
Why?
|
| Refractive Errors | 1 | 2013 | 58 | 0.020 |
Why?
|
| Isoquinolines | 1 | 2012 | 43 | 0.020 |
Why?
|
| Therapeutic Irrigation | 1 | 2012 | 45 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2013 | 238 | 0.020 |
Why?
|
| Photography | 1 | 2013 | 79 | 0.020 |
Why?
|
| Metronidazole | 1 | 2013 | 161 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2018 | 561 | 0.020 |
Why?
|
| Strabismus | 1 | 2013 | 64 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2013 | 159 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2013 | 341 | 0.020 |
Why?
|
| Eye Enucleation | 1 | 2012 | 34 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2017 | 791 | 0.020 |
Why?
|
| Choroid | 1 | 2012 | 22 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 1205 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2904 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 1410 | 0.020 |
Why?
|
| Vancomycin | 1 | 2013 | 226 | 0.020 |
Why?
|
| Radiography | 1 | 2013 | 743 | 0.020 |
Why?
|
| Genotype | 1 | 2017 | 2595 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 3829 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2020 | 3711 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 1013 | 0.020 |
Why?
|
| Binding Sites | 1 | 2013 | 1133 | 0.020 |
Why?
|
| Age Factors | 1 | 2017 | 2825 | 0.020 |
Why?
|
| Gene Expression | 1 | 2014 | 1481 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 2013 | 653 | 0.020 |
Why?
|
| Developing Countries | 1 | 2012 | 305 | 0.020 |
Why?
|
| Brain | 1 | 2021 | 3175 | 0.020 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 1999 | 61 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 1207 | 0.020 |
Why?
|
| Cell Line | 1 | 2013 | 2552 | 0.020 |
Why?
|
| Human Growth Hormone | 2 | 1999 | 74 | 0.020 |
Why?
|
| Hydrocortisone | 2 | 1999 | 215 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2012 | 757 | 0.020 |
Why?
|
| Phenotype | 1 | 2017 | 4497 | 0.020 |
Why?
|
| Risk Factors | 2 | 2018 | 11074 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 972 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2013 | 3359 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2012 | 1590 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 2004 | 82 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2008 | 892 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 2004 | 126 | 0.010 |
Why?
|
| Systole | 1 | 2004 | 195 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2004 | 295 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 303 | 0.010 |
Why?
|
| Emulsions | 1 | 2003 | 72 | 0.010 |
Why?
|
| Soybean Oil | 1 | 2003 | 71 | 0.010 |
Why?
|
| Phospholipids | 1 | 2003 | 100 | 0.010 |
Why?
|
| Tritium | 1 | 2002 | 108 | 0.010 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2002 | 43 | 0.010 |
Why?
|
| Calorimetry, Indirect | 1 | 2002 | 64 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2004 | 483 | 0.010 |
Why?
|
| Lipid Peroxidation | 1 | 2002 | 93 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2004 | 587 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 992 | 0.010 |
Why?
|
| Biological Transport | 1 | 2002 | 329 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2002 | 242 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2002 | 436 | 0.010 |
Why?
|
| Sex Factors | 1 | 2004 | 1356 | 0.010 |
Why?
|
| Norepinephrine | 1 | 1998 | 149 | 0.010 |
Why?
|
| Perception | 1 | 1999 | 231 | 0.010 |
Why?
|
| Inflammation | 1 | 2004 | 1489 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1998 | 761 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2004 | 2406 | 0.010 |
Why?
|
| Homeostasis | 1 | 1998 | 712 | 0.010 |
Why?
|